Stm functional showdeck mockup v1

1

HCT Nonbranded Speaker Training Sample Show Deck Functional Test Only Hotel TBA Dallas, Texas February 1, 2013

2

Access to Health Care Is Defined as Receiving Timely Cost-Effective Health Care

Definition • Cost-effective, appropriate

health care to achieve best possible outcome

• Timely performance of health care services

• Influenced by health care providers (HCPs), patients, and health care systems

Goal • Optimal health outcomes

Joshua TV, et al. Cancer. 2010;116(14):3469-3476.

© iStockphoto.com / sjlocke.

Presenter

Presentation Notes

Access to health care can be defined as receiving cost-effective, appropriate health care in a timely manner to achieve best possible outcome. Once an individual gains access to health care, the aim is to elicit optimal health outcomes. Accessing health care may require a complex interplay of patients and health care providers (HCPs) who work within constraints of a variety of healthcare systems and structures. Reference Joshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116(14):3469-3476.

3

The Incidence of Myeloma Peaks in Patients 65 to 74 Years of Age

0

5

10

15

20

25

30

<20 20-34 35-44 45-54 55-64 65-74 75-84 ≥85

Dia

gnos

es, %

Age at Myeloma Diagnosis

Age, years

Surveillance epidemiology and end results. SEER Stat Fact Sheets: Myeloma. National Cancer Institute Web site. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed October 21, 2012.

Presenter

Presentation Notes

Most patients with MM are diagnosed at age 55 or older.1 The median age at MM diagnosis is 69 years, which is older than was historically considered appropriate for HCT eligibility, which was less than 65 years of age.1-2 The remainder of this section details studies that show the feasibility of HCT in elderly patients with MM. References Surveillance Epidemiology and End Results. SEER stat fact sheets: Myeloma. National Cancer Institute Web site. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed October 21, 2012. Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21(suppl 7):vii143-vii150.

4

Several Reasons for Limited Access to HCT Among Elderly Patients With MM Have Been Proposed

• Possible reasons for discrepancy – Patients ≥65 years historically not candidates for HCT1

– Elderly patients excluded from clinical trials2

– Comorbidity3

– Patient preference3

“Advanced age alone should not preclude the use of effective cancer treatment that could improve quality of

life or extend meaningful survival.”4 ‒NCCN Guidelines for Senior Adult Oncology

1. Palumbo A, Gay F. Hematology Am Soc Hematol Educ Program. 2009:566-577. 2. Kumar SK, et al. Am J Hematol. 2008;83(8):614-617. 3. Majhail NS, et al. Biol Blood Marrow Transplant. 2010;16(8):1070-1075. 4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology. v2.2012.

Presenter

Presentation Notes

The data just presented may not be unexpected, given that some HCPs believe that patients 65 years or older are generally not eligible for HCT.1 In addition, elderly persons may have comorbidities that preclude them from undergoing HCT or they may prefer not to receive aggressive therapy.2 Although several possible reasons exist for elderly patients not to undergo HCT to treat hematologic malignant conditions, age alone should not dictate which treatment a patient receives.3 This notion is supported by the National Comprehensive Cancer Network (NCCN), which publishes guidelines in elderly individual oncology.3 According to the NCCN, advanced age should not prevent HCPs from using cancer therapies that may enhance quality of life and/or prolong survival.3 With respect to HCT specifically, the NCCN states that advanced age is not a contraindication against transplantation.4 However, the NCCN also acknowledges that reducing quality of life by use of therapies not expected to substantially prolong survival is not recommended.3 References Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program. 2009:566-577. doi: 10.1182/asheducation-2009.1.566. Majhail NS, Omondi NA, Denzen E, et al. Access to hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2010;16(8):1070-1075. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology. v2.2012. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. v1.2013.

Stm functional showdeck mockup v1

Education

Transcript of Stm functional showdeck mockup v1